AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17875547 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline disability
Number of subjects: 521
Study 17875547 — intervention group
Group type: EXPERIMENTAL
Intervention: Other determinants
Number of subjects: 521
Study 19266263 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized superficial thermal injury (49 degrees C for 5 min)
Number of subjects: 14
Study 15878921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiles during the early luteal phase
Number of subjects: 0
Study 15878921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiles during the mid-luteal phase
Number of subjects: 0
Study 15878921 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray data validation
Number of subjects: 0
Study 11745596 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 42
Study 11745596 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises
Number of subjects: 42
Study 9926051 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mental health service intervention
Number of subjects: 514
Study 9926051 — intervention group
Group type: COMPARATOR
Intervention: Case identification and patient interviews
Number of subjects: 514
Study 8056795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic external fixation (Clyburn device)
Number of subjects: 50
Study 8056795 — intervention group
Group type: COMPARATOR
Intervention: Static external fixation (AO/ASIF device)
Number of subjects: 50
Study 3260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.15 vol.%
Number of subjects: 20
Study 3260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane 1.68 vol.%
Number of subjects: 20
Study 3260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (during norepinephrine-induced hypertension)
Number of subjects: 20
Study 3260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (during norepinephrine-induced hypertension)
Number of subjects: 20
Study 3260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (during controlled hyperventilation)
Number of subjects: 20
Study 3260082 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (during controlled hyperventilation)
Number of subjects: 20
Study 30169740 — intervention group
Group type: EXPERIMENTAL
Intervention: COach2Quit (n = 50)
Number of subjects: 102
Study 30169740 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice + COach2Quit (n = 50)
Number of subjects: 102
Study 30169740 — intervention group
Group type: COMPARATOR
Intervention: Brief advice only (n = 52)
Number of subjects: 102
Study 30542300 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg day(-1))
Number of subjects: 67
Study 30542300 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (36 mg day(-1))
Number of subjects: 67
Study 30542300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30542300 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 67
Study 30542300 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 67
Study 26742063 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Fit! (EF!) education program for two successive school years (mean 7.6 h during 16 weeks per school per year)
Number of subjects: 1112
Study 26742063 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual curriculum)
Number of subjects: 1112
Study 24500112 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (20 g L(‐1))
Number of subjects: 10
Study 24500112 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (Control)
Number of subjects: 10
Study 22707261 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acids (HMUFA) diet
Number of subjects: 75
Study 19284927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg (for subjects aged >or=65 years)
Number of subjects: 1213
Study 19284927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg (for subjects aged 18 to 64 years)
Number of subjects: 1213
Study 19284927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 3-day run out)
Number of subjects: 1213
Study 17975239 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach to the lumbar plexus
Number of subjects: 46
Study 17975239 — intervention group
Group type: COMPARATOR
Intervention: Fascia iliaca compartment block
Number of subjects: 46
Study 17975239 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic transgluteal approach for sciatic nerve blockade
Number of subjects: 46
Study 17975239 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgluteal approach for sciatic nerve blockade
Number of subjects: 46
Study 17975239 — intervention group
Group type: COMPARATOR
Intervention: Electrostimulation of the tibial nerve
Number of subjects: 46
Study 17975239 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-injection technique for sciatic and femoral blocks
Number of subjects: 46
Study 16161895 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement during visual acuity testing
Number of subjects: 50
Study 16161895 — intervention group
Group type: COMPARATOR
Intervention: No encouragement during visual acuity testing
Number of subjects: 50
Study 11968894 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact radiant warming device with offloading therapy
Number of subjects: 36
Study 11968894 — intervention group
Group type: COMPARATOR
Intervention: Offloading therapy only
Number of subjects: 36
Study 10435378 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS (Myocardial Perfusion Scanning)
Number of subjects: 21
Study 10435378 — intervention group
Group type: EXPERIMENTAL
Intervention: RNV (Radionuclide Ventriculography)
Number of subjects: 21
Study 7480556 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 20
Study 7480556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2300087 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole plus fluorouracil
Number of subjects: 1296
Study 2300087 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole alone
Number of subjects: 1296
Study 2300087 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 1296
Study 2300087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil alone
Number of subjects: 1296
Study 368820 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33-824
Number of subjects: 26
Study 31622290 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaltenborn mobilization with thermotherapy
Number of subjects: 30
Study 31622290 — intervention group
Group type: COMPARATOR
Intervention: Kaltenborn mobilization alone
Number of subjects: 30
Study 26667107 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforming Your Life program
Number of subjects: 98
Study 26667107 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Prevention Program
Number of subjects: 98
Study 25640027 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (fURS)
Number of subjects: 30
Study 25640027 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 30
Study 23499568 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Universal Adhesive System, self-etch (PkSe)
Number of subjects: 40
Study 23499568 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Universal Adhesive System, etch-and-rinse (PkEr)
Number of subjects: 40
Study 23499568 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond Universal, self-etch (AlSe)
Number of subjects: 40
Study 23499568 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive, self-etch (ScSe)
Number of subjects: 40
Study 23499568 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive, etch-and-rinse (ScEr)
Number of subjects: 40
Study 23499568 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond Universal, etch-and-rinse (AlEr)
Number of subjects: 40
Study 21378594 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 6568
Study 21378594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6568
Study 19033449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (LER) 20 mg
Number of subjects: 8
Study 19033449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (FV) 40 mg
Number of subjects: 8
Study 19033449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (LER) 20 mg + Fluvastatin (FV) 40 mg
Number of subjects: 8
Study 17577037 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FU (3,000 mg/m2/24 hours)
Number of subjects: 145
Study 17577037 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FU/FA (2,600 mg/m2/24 hours plus dl-FA 500 mg/m2 or l-FA 250 mg/m2)
Number of subjects: 145
Study 17577037 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FU/FA/Cis (2,000 mg/m2/24 hours plus FA plus biweekly Cis 50 mg/m2)
Number of subjects: 145
Study 15539726 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air (Fio(2) 0.21)
Number of subjects: 288
Study 15539726 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen (Fio(2) > 0.21)
Number of subjects: 288
Study 11773932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic low‐molecular‐weight medium ioxaglate
Number of subjects: 30
Study 11773932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic high‐molecular‐weight medium diatrizoate
Number of subjects: 30
Study 11773932 — intervention group
Group type: COMPARATOR
Intervention: Nonionic medium iohexol
Number of subjects: 30
Study 9599891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 1:200,000
Number of subjects: 48
Study 9599891 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 48
Study 8020527 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol contrast medium at concentrations of 150, 200, 250, 300, 350, and 400 mgI/ml
Number of subjects: 4811
Study 8020527 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol contrast medium
Number of subjects: 4811
Study 2499037 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b, Introna, 3 MU 3 times weekly subcutaneously
Number of subjects: 32
Study 2499037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 1130437 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure
Number of subjects: 100
Study 1130437 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 100
Study 1130437 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medications (both groups)
Number of subjects: 100
Study 30240936 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced BW (80%BW)
Number of subjects: 24
Study 30240936 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BW (100%BW)
Number of subjects: 24
Study 30240936 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BW (120%BW)
Number of subjects: 24
Study 28829160 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialized-venous reference samples
Number of subjects: 21
Study 28829160 — intervention group
Group type: COMPARATOR
Intervention: Venous reference samples
Number of subjects: 21
Study 28829160 — intervention group
Group type: COMPARATOR
Intervention: Capillary reference samples
Number of subjects: 21
Study 28829160 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialized-venous glucose
Number of subjects: 21
Study 28829160 — intervention group
Group type: COMPARATOR
Intervention: Venous glucose
Number of subjects: 21
Study 28829160 — intervention group
Group type: COMPARATOR
Intervention: Capillary glucose
Number of subjects: 21
Study 28829160 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialization effectiveness
Number of subjects: 21
Study 28829160 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconvenience related to arterialization
Number of subjects: 21
Study 25547033 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-signal montage
Number of subjects: 15
Study 25547033 — intervention group
Group type: EXPERIMENTAL
Intervention: One-signal montage
Number of subjects: 15
Study 25547033 — intervention group
Group type: COMPARATOR
Intervention: Reference montage
Number of subjects: 15
Study 23277305 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 18624
Study 23277305 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 18624
Study 20405236 — intervention group
Group type: EXPERIMENTAL
Intervention: A-line ARX index (AAI) monitoring
Number of subjects: 60
Study 20405236 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical parameters (SCP) monitoring
Number of subjects: 60
Study 20146881 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 2 g/day for 3 months
Number of subjects: 76
Study 20146881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 17156509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (intravenous anaesthetic)
Number of subjects: 150
Study 17156509 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (volatile anaesthetic)
Number of subjects: 150
Study 17156509 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anaesthetics
Number of subjects: 150
Study 15490867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dining with a caregiver
Number of subjects: 200
Study 15490867 — intervention group
Group type: COMPARATOR
Intervention: Dining alone
Number of subjects: 200
Study 11212626 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative priming
Number of subjects: 0
Study 11212626 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing of primes
Number of subjects: 0
Study 11212626 — intervention group
Group type: COMPARATOR
Intervention: Active processing of primes
Number of subjects: 0
Study 10349437 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated and trivalent vaccine containing strains of Leptospira canicola, icterohaemorrhagiae and pomona
Number of subjects: 80
Study 10349437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8610220 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 31
Study 8610220 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine
Number of subjects: 31
Study 8610220 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 31
Study 2752395 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (2‐3 mg/kg/day for 6 months)
Number of subjects: 17
Study 2752395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 17
Study 177474 — intervention group
Group type: EXPERIMENTAL
Intervention: daily prednisone therapy
Number of subjects: 20
Study 177474 — intervention group
Group type: EXPERIMENTAL
Intervention: daily methylprednisolone
Number of subjects: 20
Study 177474 — intervention group
Group type: EXPERIMENTAL
Intervention: alternate-day methylprednisolone
Number of subjects: 20
Study 177474 — intervention group
Group type: COMPARATOR
Intervention: alternate-day therapy
Number of subjects: 20
Study 31646668 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day ibuprofen group (600 mg three times a day, N=29)
Number of subjects: 95
Study 31646668 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day ibuprofen group (N=30)
Number of subjects: 95
Study 31646668 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (N=30)
Number of subjects: 95
Study 31646668 — intervention group
Group type: EXPERIMENTAL
Intervention: Histomorphometric outcomes (all groups)
Number of subjects: 95
Study 31646668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone biomarkers (Osteocalcin and CrossLaps measured at multiple time points)
Number of subjects: 95
Study 31056404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block
Number of subjects: 123
Study 31056404 — intervention group
Group type: COMPARATOR
Intervention: Single-shot adductor canal block
Number of subjects: 123
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 on a 5-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 90 mg/m2 on a 5-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 on a 10-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (all doses and schedules)
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events for 5-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events for 10-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events for 5-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events for 10-day schedule
Number of subjects: 107
Study 28844816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 107
Study 23807352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐PRESS
Number of subjects: 64
Study 23807352 — intervention group
Group type: COMPARATOR
Intervention: trabeculectomy
Number of subjects: 64
Study 24260516 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of contrast medium (Group I)
Number of subjects: 54
Study 24260516 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL of contrast medium (Group II)
Number of subjects: 54
Study 20584756 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid and Trendelenburg position (OT)
Number of subjects: 28
Study 20584756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid (IV)
Number of subjects: 28
Study 19852841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 30
Study 19852841 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 16769272 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancement Flap (AF)
Number of subjects: 60
Study 16769272 — intervention group
Group type: COMPARATOR
Intervention: Fistulotomy with Sphincter Reconstruction (FSR)
Number of subjects: 60
Study 15622128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) in rapid cycle mode
Number of subjects: 11
Study 15622128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) in normal mode
Number of subjects: 11
Study 15622128 — intervention group
Group type: COMPARATOR
Intervention: Vagal nerve stimulation (VNS) switched off
Number of subjects: 11
Study 15314548 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (Furtulon) 800 mg/d for 2 years
Number of subjects: 287
Study 15314548 — intervention group
Group type: COMPARATOR
Intervention: OK‐432 plus 5'‐DFUR by the same regimen as in group A
Number of subjects: 287
Study 10838236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 500 ml
Number of subjects: 17
Study 10838236 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume of 1000 ml
Number of subjects: 17
Study 10838236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tidal volumes
Number of subjects: 17
Study 9182472 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 45
Study 8468435 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150-525 mg/day, mean 307 mg during last week)
Number of subjects: 127
Study 8468435 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50-175 mg/day, mean 100 mg during last week)
Number of subjects: 127
Study 3702577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 1 mg/kg body weight/day
Number of subjects: 26
Study 3702577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 4 mg/kg body weight/day
Number of subjects: 26
Study 3702577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone treatment (both dosages)
Number of subjects: 26
Study 3702577 — intervention group
Group type: COMPARATOR
Intervention: Control group (Q group with macular lesions)
Number of subjects: 26
Study 3076782 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (600 mg daily)
Number of subjects: 30
Study 3076782 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 30657017 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable fibrobronchoscopy treatment
Number of subjects: 86
Study 30657017 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine sputum suction, anti-infection drugs, sputum-reducing drugs)
Number of subjects: 86
Study 28523393 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored anesthetic masks smeared with a flavor of child's choice
Number of subjects: 60
Study 28523393 — intervention group
Group type: COMPARATOR
Intervention: Non-flavored anesthetic masks
Number of subjects: 60
Study 28523393 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored anesthetic masks
Number of subjects: 60
Study 28523393 — intervention group
Group type: COMPARATOR
Intervention: Commercially available pre-scented masks
Number of subjects: 60
Study 25046032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plexus block (PPB) with 2.5 mL 2% lignocaine injection bilaterally along with intrarectal local anaesthesia (IRLA) with 10 mL 2% lignocaine jelly
Number of subjects: 139
Study 25046032 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block (PNB) along with intrarectal local anaesthesia (IRLA) with 10 mL 2% lignocaine jelly
Number of subjects: 139
Study 25046032 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal local anaesthesia (IRLA) without any type of nerve block
Number of subjects: 139
Study 23739984 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher voltage coag mode (30 W)
Number of subjects: 40
Study 23739984 — intervention group
Group type: COMPARATOR
Intervention: Lower voltage blend mode (30 W)
Number of subjects: 40
Study 21109578 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic decisions on written words
Number of subjects: 60
Study 21109578 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic decisions on pictures of objects
Number of subjects: 60
Study 19404053 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted anterior resection
Number of subjects: 153